Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, induces greater weight loss and improves glycemic control more effectively than GLP-1 RAs alone.
Tirzepatide (5-15 mg weekly) combines GIP and GLP-1 mechanisms to achieve higher weight loss (up to 21%) than GLP-1 drugs alone. It is a potent option for those who need maximum efficacy.
StrongSupportsVERY_HIGH confidence
A recent systematic review and meta-analysis confirmed that the WL% with tirzepatide is dose-dependent and this drug appears to induce a greater WL when compared to GLP-1 RAs, (up to 7.16 kg more with 15 mg of tirzepatide) [52].
Why this rating
Supported by large controlled trials and meta-analyses.
Source
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Valeria Guglielmi et al. · Current Obesity Reports · 2023
narrative_reviewCited 31×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →